For your patients with 4-14 MHDs per month (EVOLVE-1/EVOLVE-2),
Emgality demonstrated ≥50%, ≥75%, and 100% reductions in the number of monthly MHDs from baseline for a significantly greater mean percentage of patients vs placebo1
ap<0.001 vs placebo.
In the REGAIN study, in patients with chronic migraine (≥15 headache days per month), the mean percentage of patients achieving a ≥75% and 100% reduction in monthly MHDs from baseline was not significant vs placebo over Months 1 to 3.1
Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated for the preventive treatment of migraine in adults.
SELECT IMPORTANT SAFETY INFORMATION
Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.